Document Detail


Corneal deposition after high-dose chlorpromazine hydrochloride therapy.
MedLine Citation:
PMID:  11248834     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To report a case of dermal and ocular changes after prolonged use of high-dose chlorpromazine hydrochloride therapy. METHOD: This case report includes clinical history, clinical findings, and photographic images of ocular and dermal changes. RESULTS. Chlorpromazine therapy in a cumulative dosage exceeding 1,100 g resulted in dramatic skin discoloration and multiple crystalline deposits in both corneas. Anterior capsular opacities were binocularly present. These changes were sufficient to cause reduction in visual acuity. CONCLUSIONS: Chlorpromazine deposition at high levels can cause reduction in visual acuity and significant skin discoloration.
Authors:
S K Webber; Y Domniz; G L Sutton; C M Rogers; M A Lawless
Related Documents :
3698824 - Cefoperazone-induced coagulopathy.
6153394 - Cri du chat: report of a case.
20140364 - Agranulocytosis induced by multidrug therapy in leprosy treatment: a case report.
15979284 - Thiamine deficiency and beriberi features in a patient with hyperemesis gravidarum.
22030214 - Adolescent hallux valgus deformity with bilateral absence of the hallucal sesamoids: a ...
8713934 - Biofilm formation in infectious crystalline keratopathy due to candida albicans.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Cornea     Volume:  20     ISSN:  0277-3740     ISO Abbreviation:  Cornea     Publication Date:  2001 Mar 
Date Detail:
Created Date:  2001-04-03     Completed Date:  2001-05-31     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8216186     Medline TA:  Cornea     Country:  United States    
Other Details:
Languages:  eng     Pagination:  217-9     Citation Subset:  IM    
Affiliation:
Sydney Refractive Surgery Centre, Chatswood, NSW, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antipsychotic Agents / adverse effects*
Chlorpromazine / adverse effects*
Cornea / drug effects*,  pathology
Corneal Opacity / chemically induced*,  pathology
Humans
Male
Middle Aged
Pigmentation Disorders / chemically induced*,  pathology
Schizophrenia / drug therapy
Skin / drug effects*,  pathology
Skin Pigmentation / drug effects
Visual Acuity
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 50-53-3/Chlorpromazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Superficial keratectomy and conjunctival autograft for Fuchs' superficial marginal keratitis.
Next Document:  2-Octyl cyanoacrylate medical adhesive in treatment of a corneal perforation.